Moderation: S. Rauh, D. Arnold ; Esch, LU, Lisbon, PT. Moderation: S. Rauh, Esch, LU

Transcription

1 :30-13:45 Opening and welcome Auditorium Moderation: S. Rauh, D. Arnold ; Esch, LU, Lisbon, PT 13:30-13:45 Welcome to the Conference 13:45-14:15 Keynote lecture Auditorium Moderation: 13:45-14:15 Gene profiling in breast cancer F. Cardoso, Lisbon, PT 14:30-16:00 Standards in breast cancer in 2017 Auditorium Moderation: S. Braga, I. Vaz-Luis ; Lisbon, PT, Villejuif, FR 14:30-14:40 Introduction S. Braga, Lisbon, PT 14:40-14:55 Standards of care in breast cancer: Neo-adjuvant treatment in HER2 positive I. Vaz-Luis, Villejuif, FR 14:55-15:05 Q&A 15:05-15:15 Case presentation: Complete response: Should we try to achieve it with neo-adjuvant treatment in every breast cancer? I. Vaz-Luis, Villejuif, FR 15:15-15:30 Discussion S. Braga, Lisbon, PT 15:30-15:40 Case presentation: TNBC/androgen receptor impact I. Vaz-Luis, Villejuif, FR 15:40-15:55 Discussion S. Braga, Lisbon, PT 15:55-16:00 Conclusions and future outlook I. Vaz-Luis, Villejuif, FR

2 16:30-18:00 Standards in GI cancers in 2017: Colorectal cancer Auditorium Moderation: M. Karamouzis, D. Arnold ; Athens, GR, Lisbon, PT 16:30-16:40 Introduction M. Karamouzis, Athens, GR 16:40-16:55 Standards of care in metastatic colorectal cancer: What is new in 2016/17? 16:55-17:05 Q&A 17:05-17:15 Case presentation: Right vs left side: Is this the commander for therapeutic strategy? 17:15-17:30 Discussion M. Karamouzis, Athens, GR 17:30-17:40 Case presentation: What is the standard beyond combination treatment? The field of refractory mcrc 17:40-17:55 Discussion M. Karamouzis, Athens, GR 17:55-18:00 Conclusions and future outlook :30-09:00 Keynote lecture Auditorium Moderation: 08:30-09:00 Oligometastatic disease: Only an early stage of metastasization or a new sub-entity? Implications for diagnostic and treatment strategies

3 09:00-10:30 Standards in upper GI cancers (gastroesophageal) in 2017 Auditorium Moderation: G. Lakatos, M. Ducreux ; Budapest, HU, Villejuif, FR 09:00-09:10 Introduction G. Lakatos, Budapest, HU 09:10-09:25 Standards of care in upper GI cancers M. Ducreux, Villejuif, FR 09:25-09:35 Q&A 09:35-09:45 Case presentation: Role of neo-adjuvant treatment in gastroesophageal cancers M. Ducreux, Villejuif, FR 09:45-10:00 Discussion G. Lakatos, Budapest, HU 10:00-10:10 Case presentation: Surgical limits for curative treatment in locally advanced pancreatic cancer M. Ducreux, Villejuif, FR 10:10-10:25 Discussion G. Lakatos, Budapest, HU 10:25-10:30 Conclusions and future outlook M. Ducreux, Villejuif, FR

4 11:00-12:30 Standards in GU cancers in 2017 Auditorium Moderation: M. Schmidinger, S. Oudard ; Wien, AT, Paris, FR 11:00-11:10 Introduction M. Schmidinger, Wien, AT 11:10-11:25 Standards of care in prostate cancer S. Oudard, Paris, FR 11:25-11:35 Q&A 11:35-11:45 Case presentation: Metastatic prostate cancer upon initial diagnosis S. Oudard, Paris, FR 11:45-12:00 Discussion M. Schmidinger, Wien, AT 12:00-12:10 Case presentation: Second line treatment for renal cancer M. Schmidinger, Wien, AT 12:10-12:25 Discussion S. Oudard, Paris, FR 12:25-12:30 Conclusions and future outlook M. Schmidinger, Wien, AT

5 14:00-15:30 Standards in gynaecological cancers in 2017 Auditorium Moderation: R. Eckert, S. Banerjee ; Esslingen, DE, London, GB 14:00-14:10 Introduction R. Eckert, Esslingen, DE 14:10-14:25 Standards of care in gynaecological cancers S. Banerjee, London, GB 14:25-14:35 Q&A 14:35-14:45 Case presentation: First line therapy for ovarian cancer: Where are we now? S. Banerjee, London, GB 14:45-15:00 Discussion R. Eckert, Esslingen, DE 15:00-15:10 Case presentation: If it s broken, shouldn't we fix it? Second - and further line therapy for ovarian cancer S. Banerjee, London, GB 15:10-15:25 Discussion R. Eckert, Esslingen, DE 15:25-15:30 Conclusions and future outlook S. Banerjee, London, GB

6 16:00-17:30 Standards in NSCLC in 2017 Auditorium Moderation: S. Peters, S. Rauh ; Lausanne, CH, Esch, LU 16:00-16:10 Introduction 16:10-16:25 Standards of care in NSCLC S. Peters, Lausanne, CH 16:25-16:35 Q&A 16:35-16:45 Case presentation: Immunotherapy/targeted therapy in a metastatic NSCLC patient S. Peters, Lausanne, CH 16:45-17:00 Discussion 17:00-17:10 Case presentation: Cost/benefit considerations in a metastatic NSCLC patient S. Peters, Lausanne, CH 17:10-17:25 Discussion 17:25-17:30 Conclusions and future outlook S. Peters, Lausanne, CH 17:30-18:00 Keynote lecture Auditorium Moderation: S. Braga, Lisbon, PT 17:30-18:00 Options and limits of liquid biopsies/circulating DNA in current cancer therapy K. Garm Spindler, Aarhus, DK

7 08:30-09:30 New drug toxicity Auditorium Moderation: L. Costa, S. Rauh ; Lisbon, PT, Esch, LU 08:30-08:40 Introduction 08:40-08:55 Case presentation: Late lung toxicity in anti-egfr NSCLC treatment L. Costa, Lisbon, PT 08:55-09:00 Q&A 09:00-09:10 Case presentation: Kidney toxicity of vemurafenib in melanoma L. Costa, Lisbon, PT 09:10-09:25 Discussion 09:25-09:30 Conclusions and future outlook L. Costa, Lisbon, PT 09:30-10:00 Workshop Auditorium Moderation: 09:30-09:45 Using e-tools in everyday oncology practice: Symptom monitoring L. Hochstenbach, Heerlen, NL 09:45-10:00 Discussion

8 10:30-11:30 Supportive and palliative care/symptom control Auditorium Moderation: R. Curca, F. Strasser ; Alba Iulia, RO, St Gallen, CH 10:30-10:40 Introduction R. Curca, Alba Iulia, RO 10:40-10:55 Standards in supportive and palliative care/symptom control F. Strasser, St Gallen, CH 10:55-11:00 Q&A 11:00-11:10 Case presentation: When anything but chemo is the tougher part of the job R. Curca, Alba Iulia, RO 11:10-11:25 Discussion F. Strasser, St Gallen, CH 11:25-11:30 Conclusions and future outlook R. Curca, Alba Iulia, RO 11:30-11:45 Closing remarks Auditorium Moderation: S. Rauh, D. Arnold ; Esch, LU, Lisbon, PT